Suchergebnisse - "OPSOMER MAGDA"

PubPharm (15)

1

The DIANA Study : Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years

enthalten in: Drug safety | 2021

von Violari, A. | Masenya, M. | Blanche, S. | +4

2

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

enthalten in: AIDS (London, England) | 2020

von Orkin, C. | Eron, J. | Rockstroh, J. | +9

3

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

enthalten in: AIDS research and human retroviruses | 2020

von Lathouwers, E. | Wong, E. | Brown, K. | +108

4

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

enthalten in: Antiviral research | 2019

von Eron, J. | Orkin, C. | Cunningham, D. | +111

5

Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability

enthalten in: Clinical pharmacology in drug development | 2019

von Crauwels, H. | Baugh, B. | Van Landuyt, E. | +3

6

Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir

enthalten in: Drugs in R&D | 2018

von Opsomer, M. | Dimitrova, D. | Verspeelt, J. | +10

ErratumIn: Drugs R D. 2018 Aug 6;:. - PMID 30079430

7

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD) : a phase 3, randomised, non-inferiority trial

enthalten in: The lancet. HIV | 2018

von Orkin, C. | Molina, J. | Negredo, E. | +110

CommentIn: Lancet HIV. 2018 Jan;5(1):e3-e5. - PMID 28993181

8

Darunavir/cobicistat once daily for the treatment of HIV

enthalten in: Expert review of anti-infective therapy | 2015

von Kakuda, T. | Crauwels, H. | Opsomer, M. | +5

9

Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients : week 48 results of the ARIEL trial

enthalten in: The Pediatric infectious disease journal | 2015

von Violari, A. | Bologna, R. | Kumarasamy, N. | +7

10

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

enthalten in: AIDS research and therapy | 2014

von Tashima, K. | Crofoot, G. | Tomaka, F. | +9